Synthesis of key intermediate of KRAS G12C inhibitor compound
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new medical treatments for patients with pancreatic cancer, lung adenocarcinoma, or colorectal cancer, particularly those with KRAS mutations, as KRAS mutations confer resistance to EGFR targeted therapies and are common in these cancers, necessitating improved synthesis methods for KRAS G12C inhibitors.
Innovation Solution
An improved, efficient, scalable process is developed for synthesizing intermediate compounds, such as compound 5M, which are crucial for KRAS G12C inhibitors, using specific chemical reactions and crystalline forms to enhance the production efficiency and purity of these inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional synthesis methods are used for KRAS G12C inhibitors, then the production process is simpler, but the purity and efficiency of the intermediate compounds are insufficient
Solution Approach 1:
The synthesis process is divided into distinct stages with specific intermediates (compounds of formulas (I), (II), and (III)) isolated and characterized at each step. This segmentation allows for controlled purification and quality assurance at each stage, ensuring high purity of the final intermediate compound while maintaining a manageable process complexity through systematic organization.
Solution Approach 2:
The patent employs specific reaction conditions and parameters including controlled temperatures, solvent systems, and stoichiometric ratios to optimize the synthesis. By carefully adjusting these parameters, the process achieves high purity intermediates through selective crystallization and reaction control without requiring excessively complex equipment or procedures.
2Productivity
If scalable synthesis process is implemented, then the production volume increases, but the manufacturing complexity increases
Solution Approach 1:
The patent establishes a predefined multi-step synthesis pathway with clearly defined intermediates and reaction conditions that can be scaled systematically. By preparing and characterizing each intermediate compound with specified purity requirements before proceeding to the next step, the process enables scalable production while maintaining control through predetermined protocols rather than requiring complex real-time decision systems.
Solution Approach 2:
The synthesis process utilizes crystallization and phase separation techniques to purify intermediates at each stage. These phase transitions provide natural separation and purification mechanisms that can be scaled up without proportionally increasing process complexity, as the same physical principles apply whether processing small or large volumes.
Data Source
AI summary
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structureuseful for the synthesis of compounds that target KRAS G12C mutations, such as